|
- Medical Information | SK life science - MedAffairs
Product Pipeline At SK life science, we’re dedicated to the discovery and development of new treatments for CNS disorders Find out about the next generation of CNS medicines View Global Pipeline
- SK Life Science, Inc.
We are dedicated to finding new treatments that will address the needs of those living with a central nervous system (CNS) disorder and to change the future of cancer care
- Our Medicines | SK life science - MedAffairs
XCOPRI has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents, including inhibiting the persistent component of the sodium current It is also a positive allosteric modulator of the γ-aminobutyric acid (GABA A) ion channel Prescribing Information IN DEVELOPMENT View Global Pipeline
- SKLife-CorporateFactsheet-7. 18. 19 - About SK life science
We have a pipeline of eight products in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others
- Publications | SK life science - MedAffairs
There is no guarantee that the pipeline products or investigational uses will receive FDA approval SK Life Science, Inc does not recommend use of its products inconsistent with the full prescribing information
- SK Biopharmaceucals Announces 100,000 Pa ents Globally Have Been . . .
n their expansion into oncology SK Biopharmaceucals and SK Life Science, Inc have a pipeline of eight compounds in development in both CNS disorders a d oncology Addionally, through SK Life Science Labs, its R D subsidiary in the U S , SK Biopharmaceucals is focused on the discovery of new treatments in oncology For more informaon, visit
- SK life science Initiates Phase 3 Clinical Trial of Carisbamate for . . .
The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology
- SK Biopharmaceuticals Enters Greater China Out-Licensing 6 Clinical . . .
The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology
|
|
|